[1] ParkinD M, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000[J]. Int J Cancer, 2001, 94(2):153
[2] Martin-Hirsch P P, Paraskevaidis E, Bryant A, et al. Surgery for cervical intraepithelial neoplasia[J]. Cochrane Database Syst Rev,2013, 12:CD001318
[3] Melsheimer P, Vinokurova S, Wentzensen N, et al. DNA aneuploidy and integration of human papillomavirus type 16 E6/E7 oncogenes in Intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri[J]. Clin Cancer Res, 2004, 10(9):3059
[4] Sudol M. Yes-associated protein(YAP65) is a proline-richphosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product[J]. Oncogene, 1994, 9(8):2145
[5] Overholtzer M, Zhang J, Smolen G A, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon[J].Proc Natl Acad Sci U S A, 2006, 103(33):12405
[6] Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer[J]. Curr Opin Cell Biol,2008, 20(6):638
[7] Guo J, Kleeff J, Zhao Y, et al. Yes-associated protein (YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma[J]. Int J Mol Med, 2006, 17(5):761
[8] Lam-Himlin D M, Daniels J A,Gayyed M F, et al. The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway[J]. Int J Gastrointest Cancer, 2006, 37(4):103
[9] Zhao B, Wei X M, Li W Q, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control[J]. Genes Dev, 2007, 21(21):2747
[10] Wang Y, Dong Q, Zhang Q, et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer[J]. Cancer Sci, 2010, 101(5):1279
[11] Liu T B, Liu Y D, Gao H Y, et al. Clinical significance of yes-associated protein overexpression in cervical carcinoma: the differential effects based on histotypes[J]. Int J Gynecol Cancer, 2013, 23(4):735
[12] Xiao H, Wu L A, Zheng H X, et al. Expression of Yes-associated protein in cervical squamous epithelium lesions[J]. Int J Gynecol Cancer, 2014, 24(9):1575
[1]李晶晶,赵卫东,王德华.72例宫颈癌术后并发症及卵巢功能分析[J].天津医科大学学报,2014,20(01):63.
[2]崔丽阳,岳天孚.高危型HPV持续感染的影响因素探讨[J].天津医科大学学报,2014,20(03):209.
CUI Li-yang,YUE Tian-fu.Investigation on factors for persistent high-risk human papilloma virus infection[J].Journal of Tianjin Medical University,2014,20(04):209.
[3]孙 艳,齐 政,王德华,等.miR-186通过靶定CEA抑制宫颈癌细胞转移[J].天津医科大学学报,2016,22(04):288.
SUN Yan,QI Zheng,WANG De-hua,et al.miR-186 inhibits cervical cancer migration by targetting CEA[J].Journal of Tianjin Medical University,2016,22(04):288.
[4]曲首辉,鲍志敏,刘荣欣.TCT、活检病理在宫颈上皮瘤变及早期宫颈癌诊断中的价值分析[J].天津医科大学学报,2018,24(04):360.
[5]陈 辉,樊茹佳,丁继侠.宫颈癌组织中Foxm1、ANGPTL4蛋白表达及临床意义[J].天津医科大学学报,2019,25(05):510.
CHEN Hui,FAN Ru-jia,DING Ji-xia.Expression and clinical significance of Foxm1 and ANGPTL4 protein in cervical cancer tissues[J].Journal of Tianjin Medical University,2019,25(04):510.
[6]闫晓芳,谢 虹,汤 华.miR-3685通过靶向CTTN抑制宫颈癌细胞的迁移、侵袭及生长[J].天津医科大学学报,2020,26(01):8.
YAN Xiao-fang,XIE Hong,TANG Hua.miR-3685 inhibits migration, invasion and growth of cervical cancer cells by targeting CTTN[J].Journal of Tianjin Medical University,2020,26(04):8.
[7]白丽丽,汤华.TNF-α诱导的circMAN1A2促进宫颈癌细胞的迁移、侵袭和增殖[J].天津医科大学学报,2020,26(02):103.
BAI Li-li,TANG Hua.TNF-α-induced circMAN1A2 promotes migration, invasion and proliferation of cervical cancer cells[J].Journal of Tianjin Medical University,2020,26(04):103.
[8]赵敬,杨金豪,张文帆,等.2009—2020年中国女性生殖道支原体、衣原体和人乳头瘤病毒感染与宫颈癌发生相关性的Meta分析[J].天津医科大学学报,2021,27(04):396.
ZHAO Jing,YANG Jin-hao,ZHANG Wen-fan,et al.A meta-analysis of association between Mycoplasma,Chlamydia infection and Human papillomavirus infection in female genital tract and cervical cancer in China from 2009 to 2020[J].Journal of Tianjin Medical University,2021,27(04):396.
[9]赵敬,杨金豪 综述,常艳敏,等.中国宫颈癌DNA甲基化标志物的研究进展[J].天津医科大学学报,2021,27(05):545.
[10]李广宁 综述,曹文枫 审校.女性生殖系统双原发癌的研究进展[J].天津医科大学学报,2021,27(06):655.